Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Free Cash Flow (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Free Cash Flow for 4 consecutive years, with -$16.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 34.1% to -$16.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$104.7 million through Dec 2025, up 5.58% year-over-year, with the annual reading at -$104.7 million for FY2025, 5.02% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$16.0 million at Century Therapeutics, up from -$25.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $83.0 million in Q1 2022, with the low at -$48.3 million in Q3 2022.
  • Average Free Cash Flow over 4 years is -$20.9 million, with a median of -$27.7 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 64.95% in 2023, while the deepest fall reached 136.4% in 2023.
  • Over 4 years, Free Cash Flow stood at -$29.2 million in 2022, then grew by 6.74% to -$27.2 million in 2023, then rose by 10.98% to -$24.2 million in 2024, then skyrocketed by 34.1% to -$16.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$16.0 million, -$25.8 million, and -$27.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.